To compare the diagnostic value of the simple pressure algometry technique coupled with a wind-up assessment and a more sophisticated and time-consuming BR or NFR testing, we defined the cut-off values for BR and NFR R3 thresholds as described above.
Because we intended to calculate the probability of any abnormal pediatric phenotype when the CNV was identified on prenatal microarray testing, we defined the frequency of disease (P(D)) to be 5.12%, which is derived from the work of Baird et al., who estimated the population frequency of diseases with an important genetic component among individuals younger than 25too be 53 in 1,000.
For statistical comparison tests we defined the significance level as P≤0.05 with no adjustments for multiple comparisons.
In the presentation of the results for both tests, we defined the "correct" option when at least one of the reviewers stated the purchase or drug use period as correct, and "error" when both reviewers agreed that it was erroneous, and the rest as "non-solvable".
In the test research, we defined the entity-level criteria according to the entered diagnosis and ordered treatments rather than the diagnostic criteria of the disease.
For those SSTI episodes where a microbiology test was ordered, we defined the "index specimen" as being the specimen from which the first clinically-relevant organism was isolated, or the first specimen obtained during the relevant time period if no organism was isolated.
On the testbed we defined an experiment with 106 nodes representing a highway scenario with three different communication patterns: single-hop topology broadcasting of CAM messages by all nodes, multi-hop geo-broadcasting of DENM messages originating from six different nodes (ID 1 6), and IPv6 unicast VoIP communication between two other nodes (from nodes 99 to 101).
For the test, we defined five subsets: [mg1, 2, 3, 4], [mg1, 2, 3, 5], [mg1, 2, 4, 5], etc. and selected the candidate genes.
When evaluating the inhibitory activity of the tested compounds on RIP3, we defined the inhibition rate as [1-signal (+compounds)/signal (−compounds)] × 100%.
In 2009, we performed such a characterization using the method of Schorlemmer and Woessner (2008), and we defined the testing region using criteria similar to Schorlemmer et al. (2010a) but also by taking into account the availability of models, the sufficiency of the input data, and potential applicability of forecasting results to the practical problems of risk mitigation.
In order to test for group level differences we defined the following contrasts at the first level lip purse versus rest; executed movement of left intact arm versus rest; imagined movement of each hand versus rest.
